March 14, 2017
Daiichi Sankyo said on March 13 that it has inked a drug discovery and licensing accord with Heptares Therapeutics, focusing on a single G protein-coupled receptor (GPCR) nominated by the Japanese company that plays a crucial role in relieving pain...read more